RARE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RARE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Ultragenyx Pharmaceutical's enterprise value is $3,065.6 Mil. Ultragenyx Pharmaceutical's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $434.2 Mil. Therefore, Ultragenyx Pharmaceutical's EV-to-Revenue for today is 7.06.
The historical rank and industry rank for Ultragenyx Pharmaceutical's EV-to-Revenue or its related term are showing as below:
During the past 13 years, the highest EV-to-Revenue of Ultragenyx Pharmaceutical was 24209.28. The lowest was 4.71. And the median was 25.15.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2024-05-02), Ultragenyx Pharmaceutical's stock price is $43.20. Ultragenyx Pharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $5.89. Therefore, Ultragenyx Pharmaceutical's PS Ratio for today is 7.33.
The historical data trend for Ultragenyx Pharmaceutical's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ultragenyx Pharmaceutical Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-Revenue | Get a 7-Day Free Trial | 16.89 | 29.87 | 14.61 | 6.98 | 7.83 |
Ultragenyx Pharmaceutical Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EV-to-Revenue | Get a 7-Day Free Trial | 6.98 | 5.82 | 6.88 | 5.31 | 7.83 |
For the Biotechnology subindustry, Ultragenyx Pharmaceutical's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Ultragenyx Pharmaceutical's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
Ultragenyx Pharmaceutical's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 3065.634 | / | 434.249 | |
= | 7.06 |
Ultragenyx Pharmaceutical's current Enterprise Value is $3,065.6 Mil.
Ultragenyx Pharmaceutical's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $434.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ultragenyx Pharmaceutical (NAS:RARE) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
Ultragenyx Pharmaceutical's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 43.20 | / | 5.893 | |
= | 7.33 |
Ultragenyx Pharmaceutical's share price for today is $43.20.
Ultragenyx Pharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.89.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Emil D Kakkis | director, 10 percent owner, officer: President & CEO | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Thomas Richard Kassberg | officer: CBO & Senior Vice President | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Howard Horn | officer: Chief Financial Officer | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Theodore Alan Huizenga | officer: Controller and PAO | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Erik Harris | officer: EVP & Chief Commercial Officer | 60 LEVERONI COURT, NOVATO CA 94949 |
Sanders Corazon (corsee) D. | director | C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729 |
John Richard Pinion | officer: See Remarks | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Karah Herdman Parschauer | officer: EVP and General Counsel | 60 LEVERONI COURT, NOVATO CA 94949 |
Eric Crombez | officer: EVP and Chief Medical Officer | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Dennis Karl Huang | officer: SVP and Chief Tech Ops Officer | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Camille L Bedrosian | officer: EVP and Chief Medical Officer | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Mardi Dier | officer: CFO & Executive Vice President | C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301 |
Amrit Ray | director | 60 LEVERONI COURT, NOVATO CA 94949 |
William Aliski | director | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Shalini Sharp | officer: CFO & Senior Vice President | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
From GuruFocus
By Marketwired • 10-19-2023
By Marketwired • 10-26-2023
By Marketwired • 10-23-2023
By Marketwired • 10-17-2023
By Marketwired • 07-06-2023
By GlobeNewswire • 01-07-2024
By Marketwired • 10-20-2023
By Marketwired • 09-20-2023
By GlobeNewswire • 09-20-2023
By Marketwired • 10-12-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.